Acumen Pharmaceuticals Inc (ABOS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.18+2.91%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABOS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | 10.8 | 2.4 | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 86.8 | 104.9 | 93.8 | 42.3 | 32.4 | 12.3 | 8.0 |
| Operating Income | (105.4) | (123.8) | (114.0) | (61.1) | (45.2) | (19.6) | (7.9) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 4.2 | 4.1 | 0.6 | 0.0 | — | — |
| Interest & Investment Income | 5.1 | 7.4 | 14.3 | 10.8 | — | — | — |
| Net Interest Expenses | — | — | — | (10.2) | — | — | — |
| Other Non-Operating Income / Expenses | 0.4 | 2.5 | 11.7 | 8.8 | 2.4 | (81.0) | 0.6 |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (105.0) | (121.3) | (102.3) | (52.4) | (42.9) | (100.6) | (7.3) |
| Per Share | |||||||
| Basic EPS | (1.45) | (2.00) | (1.71) | (1.08) | (1.06) | (5.02) | — |
| Diluted EPS | (1.45) | (2.00) | (1.71) | (1.08) | (1.06) | (5.02) | — |
| Basic Weighted Avg Shares | 72.3 | 60.6 | 60.0 | 48.6 | 40.6 | 20.1 | — |
| Diluted Weighted Avg Shares | 72.3 | 60.6 | 60.0 | 48.6 | 40.6 | 20.1 | — |
| Supplemental | |||||||
| EBIT | (105.4) | (123.8) | (114.0) | (61.1) | (45.2) | (19.6) | (7.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.